Profilo
Thamil Annamalai formerly worked at XenoPort, Inc., as Senior Director from 2001 to 2013, Protagonist Therapeutics, Inc., as Senior Director-Preclinical Development from 2014 to 2017, Essential Therapeutics, Inc., as Research Pharmacologist, IntraBiotics Pharmaceuticals, Inc., as Manager-Preclinical Research from 1997 to 2001, and Nycomed Salutar, Inc., as Research Scientist.
Ms. Annamalai received her graduate degree from the University of Madras and graduate degree from Pachaiyappas College.
Precedenti posizioni note di Thamil Annamalai
| Società | Posizione | Fine |
|---|---|---|
| PROTAGONIST THERAPEUTICS, INC. | Corporate Officer/Principal | 01/01/2017 |
| XENOPORT, INC. | Direttore/Membro del Consiglio | 01/01/2013 |
IntraBiotics Pharmaceuticals, Inc.
 IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections. | Corporate Officer/Principal | - |
Essential Therapeutics, Inc.
 Essential Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections | Corporate Officer/Principal | - |
| Nycomed Salutar, Inc. | Direttore Tecnico/Scientifico/R&S | 01/01/1994 |
Formazione di Thamil Annamalai
| University of Madras | Graduate Degree |
| Pachaiyappas College | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| PROTAGONIST THERAPEUTICS, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
IntraBiotics Pharmaceuticals, Inc.
IntraBiotics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology IntraBiotics, a developer of antibiotics and antifungals is focused on one drug candidate, iseganan hydrochloride oral solution, which would be used for the prevention of ventilator-associated pneumonia and to help cystic fibrosis patients fight respiratory infections. | Health Technology |
Essential Therapeutics, Inc.
Essential Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Essential Therapeutics, Inc. manufactures pharmaceutical goods for viral and fungal infections | Health Technology |
| Nycomed Salutar, Inc. | |
XenoPort, Inc.
 XenoPort, Inc. Pharmaceuticals: MajorHealth Technology XenoPort, Inc. operated as a biopharmaceutical company. Its products included horizant and regnite. The company was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on December 17, 1999 and was headquartered in Atlanta, GA. | Health Technology |
- Borsa valori
- Insiders
- Thamil Annamalai
